Request Discount

Hemophilia Treatment Market (Type - Hemophilia A, Hemophilia B, and Hemophilia C; Product - Plasma Derived Coagulation Factor Concentrates, Desmopressin, Recombinant Coagulation Factor Concentrates, and Antifibrinolytic Agents; Therapy - ITI Therapy, Gene Therapy, and Replacement Therapy): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025

  • Published : July, 2019

  • Rep Id : HC0617

  • Category : Healthcare & Medical Devices

  • Status : Published

This report provides exclusive insights into the COVID-19 impact on the Hemophilia Treatment Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Hemophilia Treatment Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Hemophilia Treatment Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.

A recent report published by Infinium Global Research on the hemophilia treatment market provides an in-depth analysis of segments and sub-segments in the global as well as regional hemophilia treatment market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional hemophilia treatment market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global hemophilia treatment market. According to the report, the global hemophilia treatment market is projected to grow at a CAGR of 5.3% over the forecast period of 2019-2025.

Market Insight

Hemophilia is a genetic disorder of bleeding which reduces blood clotting, as it deficiencies of blood-clotting proteins. This disorder mainly found in males. Hemophilia patient doesn’t bleed faster than normal people but they blood for more time after an injury than others. The treatment of hemophilia includes replacement of needed clotting factor through a tube inserted in the vein. Two methods of treatment are mostly used in hemophilia treatment such as on-demand treatment in which medicine used for prolonged bleeding and preventive treatment in which medicine doses used for control muscle damage and bleeding.

The global hemophilia treatment market is primarily driven by the rising prevalence rate of bleeding disorder and their increasing severity, increasing research activities and advancing medical knowledge. Moreover, the rising use of prophylactic treatment in hemophilia, technological advancements, the invention of new coagulating factors, flourishing biotechnology filed is expected to fuel the market growth in the near future. However, the growing adoption of vegetarian food and increasing storage and maintenance cost of the vaccine is expected to hinder the demand for the global hemophilia treatment market. Nonetheless, rising awareness among people, escalating R&D focused on identifying curative agents is anticipated to create a new opportunity for the global hemophilia treatment market.

On the basis of region, the global hemophilia treatment market is bifurcated into North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. North America held the largest revenue share for the global hemophilia treatment market in 2018 owing to the rising prevalence rate of a bleeding disorder, growing preference for prophylaxis treatment,  and their increasing severity, the growing effective gene therapy, presence of major players in the region. The Asia Pacific is estimated to be the fastest-growing region within the projected years owing to the rising use of recombinant products, and growing prevalence rate of hemophilia disorder. North America is followed by Europe and the Asia Pacific.

Global Hemophilia Treatment Market

Segment Covered

The report on the global hemophilia treatment market covers segments such as type, product, and therapy. On the basis of type, the sub-markets include hemophilia A, hemophilia B, and hemophilia C. On the basis of product, the sub-markets include plasma derived coagulation factor concentrates, desmopressin, recombinant coagulation factor concentrates, and antifibrinolytic agents. On the basis of therapy, the sub-markets include ITI therapy, gene therapy, and replacement therapy. 

Companies Profiled:

The report provides profiles of the companies in the market such as Pfizer, Baxter International, Grifols, CSL Ltd., Baxalta, Octapharma, Novo Nordisk, Bayer, Hospira, and Biogen Idec. 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the hemophilia treatment market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.

Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount